IP Library Granted Patent US 11,090,366
Granted Patent B2
US 11,090,366 · App. 14/355,308 · Granted Aug 17, 2021

Compositions and methods for reducing oral biofilm

Inventors: Karen LoVetri (Winnipeg, CA); Srinivasa Madhyastha (Winnipeg, CA); Nandadeva Yakandawala (Winnipeg, CA); Purushottam V. Gawande (Winnipeg, CA); Gord Froehlich (Selkirk, CA)
Assignee: Kane Biotech Inc.
A61K38/40A61K8/365A61K8/44A61K8/64A61K9/0063A61K9/127A61K9/5153A61K31/194A61K31/198A61K31/315A61K45/06A61K47/60A61Q11/00A61Q17/005A61K2800/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,090,366
App. No.
14/355,308
Granted
Aug 17, 2021
Kind
B2
Abstract

Compositions comprising iron-sequestering glycoproteins, chelating agents, stabilizing agents, binding agents, surfactants, fluorides, antimicrobials and a pH adjuster or buffer for the prevention and treatment of oral cavity diseases caused by dental plaque/biofilm, such as dental caries, gingivitis and periodontitis, through anti-infective properties are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in polymicrobial dental biofilms. The composition may be in the form of wash, rinse, soak, paste, gel, spray, or other suitable form. Additionally, the invention offers an efficient method of delivering the formulated composition containing a PEGylated or fluorinated iron-sequestering glycoprotein and one or two chelating agents or chelating agents alone using either a liposomal or a nanoparticle delivery system.

Claims (19)

1. A composition for reducing bacterial biofilm formation in the oral cavity, the composition consisting essentially of:

(a) ethylenediaminetetraacetic acid (EDTA) between about 250 mg/L and about 1000 mg/L of the composition;

(b) a citrate selected from one or more of sodium citrate and potassium citrate, wherein the citrate is at a concentration between about 1600 mg/L and about 3200 mg/L; and

(c) a zinc salt selected from the group consisting of zinc lactate, zinc gluconate, zinc citrate, and zinc chloride, wherein said zinc salt is at a concentration of 25 mg/L to 100 mg/L,

prepared as one or more of a mouthwash, an oral rinse, a spray, an abrasive dentifrice gel, a dentifrice, a denture wash, a denture soak, a topical agent, a denture adhesive, a denture cement, a lozenge, and a pet chew biscuit.

2. The composition of claim 1 , wherein the bacteria is selected from the group consisting of Streptococcus mutans, Streptococcus sobrinus, Streptococcus sanguis ( sanguinis ), Streptococcus gordonii, Streptococcus oralis, Streptococcus mitis, Actinomyces odontolyticus, Actinomyces viscosus, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Bacteroides forsythus, Treponema denticola, Fusobacterium nucleatum, Campylobacter rectus, Eikenella corrodens, Veillonella spp., Micromonas micros, Porphyromonas cangingivalis, Haemophilus actinomycetemcomitans Actinomyces spp., Bacillus spp., Mycobacterium spp., Fusobacterium spp., Streptococcus spp., Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalectiae, Proteus mirabilis, Klebsiella pneumoniae, E. coli, Acinetobacter spp., Enterococcus spp., Prevotella spp., Porphyromonas spp., Clostridium spp., Stenotrophomonas maltophilia and P. cangingivalis.

3. The composition of claim 1 , further comprising one or more ingredients selected from the group consisting of: water, a buffer, a stabilizing agent, a binding agent, a gelling agent, a desensitizing agent, a teeth whitening agent, an antiplaque deposition aide, a surfactant, a herbal, a vitamin, a mineral, a pH adjuster, a flavor, and a color.

4. The composition of claim 1 , wherein the EDTA is disodium EDTA.

5. The composition of claim 4 , wherein the disodium EDTA is present at about 500 mg/L.

6. The composition as claimed in claim 1 , wherein the composition comprises a liposomal or nanoparticle delivery system.

7. The composition of claim 1 , wherein said EDTA is in the form of a disodium or tetrasodium salt.

8. A composition for reducing bacterial biofilm formation in the oral cavity, the composition consisting essentially of: sodium citrate in a concentration of about 3.2 mg/ml, disodium EDTA in a concentration of about 0.5 mg/ml, and a zinc salt selected from the group consisting of zinc lactate, zinc gluconate, zinc citrate, and zinc chloride, said zinc salt in a concentration of about 0.025 to 0.100 mg/ml,

prepared as one or more of a mouthwash, an oral rinse, a spray, an abrasive dentifrice gel, a dentifrice, a denture wash, a denture soak, a topical agent, a denture adhesive, a denture cement, a lozenge, and a pet chew biscuit.

9. The composition of claim 8 , further comprising one or more selected from the group consisting of: water, a buffer, a stabilizing agent, a binding agent, a gelling agent, a desensitizing agent, a teeth whitening agent, an antiplaque deposition aide, a surfactant, a herbal, a vitamin, a mineral, a pH adjuster, a flavor, and a color.

10. A composition for reducing bacterial biofilm formation in the oral cavity, the composition comprising an antimicrobial agent consisting essentially of:

(a) ethylenediaminetetraacetic acid (EDTA) between about 250 mg/L and about 1000 mg/L of the composition; and

(b) a citrate selected from one or more of sodium citrate and potassium citrate, wherein the citrate is at a concentration between about 1600 mg/L and about 3200 mg/L,

prepared as one or more of a mouthwash, an oral rinse, a spray, an abrasive dentifrice gel, a dentifrice, a denture wash, a denture soak, a topical agent, a denture adhesive, a denture cement, a lozenge, and a pet chew biscuit.

11. A method of reducing bacterial biofilm formation in the oral cavity comprising orally administering the composition of claim 1 , wherein the bacteria biofilm is caused by at least one of the bacteria selected from the group consisting of Streptococcus mutans, Steptococcus sobrinus, Streptococcus sanguis ( sanguinis ), Streptococcus gordonii, Streptococcus oralis, Streptococcus mitis, Actinomyces odontolyticus, Actinomyces viscosus, Aggregatibacter actinomycetemcomitans. Porphyromonas gingivalis, Prevotella intermedia, Bacteroides forsythus, Treponema denticola, Fusobacterium nucleatum, Campylobacter rectus, Eikenella corrodens, Veillonella spp., Micromonas micros, Porphyromonas cangingivalis, Haemophilus actinomycetemcomitans Actinomyces spp., Bacillus spp., Mycobacterium spp., Fusobacterium spp., Streptococcus spp., Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalectiae, Proteus mirabilis, Klebsiella pneumoniae, E. coli, Acinetobacter spp., Enterococcus spp., Prevotella spp., Porphyromonas spp., Clostridium spp., Stenotrophomonas maltophilia and P. cangingivalis.

Assignments (2)
SECURITY INTEREST Recorded Nov 9, 2020
From: KANE BIOTECH INC.
To: PIVOT FINANCIAL INC.
Reel/Frame 054307/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2017
From: LOVETRI, KAREN; MADHYASTHA, SRINIVASA; YAKANDAWALA, NANDADEVA; GAWANDE, PURUSHOTTAM V.; FROEHLICH, GORD
To: KANE BIOTECH INC.
Reel/Frame 041601/0803 →
Cited By (1)
US 12,478,681